In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.
about
Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemiaRole of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learnedThe growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABLInhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemiaCurrent concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemiaResistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment optionsConformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036A Mechanism for Tunable Autoinhibition in the Structure of a Human Ca2+/Calmodulin- Dependent Kinase II HoloenzymeStructural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase DomainAllosteric interactions between the myristate- and ATP-site of the Abl kinaseAbcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitroA target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALLInhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cellsMolecular Determinants Underlying Binding Specificities of the ABL Kinase Inhibitors: Combining Alanine Scanning of Binding Hot Spots with Network Analysis of Residue Interactions and CoevolutionFirst-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia.Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.Emerging drugs for chronic myeloid leukemia.Selecting the best frontline treatment in chronic myeloid leukemiaPH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous LeukemiaPractical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl.Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Locking Src/Abl Tyrosine Kinase Activities Regulate Cell Differentiation and Invasion of Human Cervical Cancer Cells Expressing E6/E7 Oncoproteins of High-Risk HPVTransforming and tumorigenic activity of JAK2 by fusion to BCR: molecular mechanisms of action of a novel BCR-JAK2 tyrosine-kinase.Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinibAn update on dual Src/Abl inhibitors.Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma.The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinibTargeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studiesBosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitorsLRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNFα expression and receptor tyrosine kinase signalingIn vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib.Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation.
P2860
Q24607114-85F0D17D-CCA6-49F5-B344-6FEFC7B90FA1Q26738514-8E1C19F8-D805-4ECE-A123-6CA9A13BEA96Q26866312-508DCB4D-9459-4B4D-B661-EA82E4B7ED46Q27004027-80075675-CCAC-4FCB-A994-74D883C070DAQ27025242-292D1146-8CA7-4C93-B76D-4D1AA2BD9596Q27028181-F67B35FA-2343-4220-B047-461C21EEBEB0Q27667482-68628784-9D22-4C3B-B506-026B6CE27A76Q27672798-F1A498A9-61EA-4955-A8C3-9D10070158DFQ27678454-5593041D-3135-422D-A4AF-1B1EFA5C3A89Q28476718-22741180-191E-4D06-AA3C-79ED8FFB7B59Q28477903-4CC764B8-D4E2-4F76-8209-B486B311F98BQ28534337-6F823AA3-312B-42BD-8BE1-35D60215B2F6Q28545195-F2B128D7-1C39-4A99-A313-FEF61027E058Q28548366-DFD31D50-8719-44CE-85ED-0D4FEDA35022Q33392977-E99EFCF7-8877-4BEC-9376-30E909ACAD69Q33403826-4A1B668E-BC9C-4A4C-B949-F313653BBBA7Q33412495-E2744B74-281F-428F-BDA6-F5A286859512Q33414487-5436519E-D6A0-4B61-939B-4C59C7C5D7AEQ33434675-E007D364-6F91-4016-9DC3-3D23AE66EB7AQ33536762-8F924378-5A07-43E4-98C4-35026E3A94B8Q33764253-452F8F46-EA5B-42C4-99C0-30143829F8CBQ33779210-185AA246-3C2C-46E8-BA17-0590AECABB15Q33806617-87493E44-5491-42D5-BB52-0D61B7F5624AQ33878636-546F2483-3EE3-44C6-9446-A9788E0AF0D3Q34052015-23860460-61D3-495E-9B44-925210E9B7CFQ34121339-1146BD97-DBB4-4836-9D3A-AF625AADE1ABQ34123748-E9AC7E55-BEB4-47D0-B365-0207E6E040B4Q34182738-836E12A2-4983-492F-895C-C4FD9AAAAD45Q34210528-891FD8CF-B210-45B3-941D-05CA165FA1D1Q34270677-602D423C-1B32-4448-825F-CA79D39C6415Q34297594-BC6018FB-C8D8-455C-A8EC-5F5E9A35F3D4Q34763374-B7271C31-6E44-4A88-A9F5-EFC3762CF5A3Q35008618-329C8FAA-25AC-4ECE-8EB4-A76F96E05FF5Q35070978-26217F15-C777-44F5-95D2-804D533BFBEAQ35377275-8EEE1775-13B1-4DB1-8E2B-7EF6212C444EQ35539318-9FBB57F1-D0DB-4070-A734-B2484A8D2FABQ35743878-8894808F-E17D-494A-A81D-91B40E4CC070Q35803259-C8E4B872-2AE6-4BA4-B7BC-7B98EB5DE1C7Q35819214-DCDF7F6E-1276-4A3D-95F5-965D674AEE28Q36169317-0792CA27-3CF5-42DD-86AC-60F1A39C34B5
P2860
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
In vitro and in vivo activity ...... ant Bcr-Abl+ neoplastic cells.
@ast
In vitro and in vivo activity ...... ant Bcr-Abl+ neoplastic cells.
@en
In vitro and in vivo activity ...... ant Bcr-Abl+ neoplastic cells.
@nl
type
label
In vitro and in vivo activity ...... ant Bcr-Abl+ neoplastic cells.
@ast
In vitro and in vivo activity ...... ant Bcr-Abl+ neoplastic cells.
@en
In vitro and in vivo activity ...... ant Bcr-Abl+ neoplastic cells.
@nl
prefLabel
In vitro and in vivo activity ...... ant Bcr-Abl+ neoplastic cells.
@ast
In vitro and in vivo activity ...... ant Bcr-Abl+ neoplastic cells.
@en
In vitro and in vivo activity ...... ant Bcr-Abl+ neoplastic cells.
@nl
P2093
P50
P1433
P1476
In vitro and in vivo activity ...... ant Bcr-Abl+ neoplastic cells.
@en
P2093
Addolorata Maria Luce Coluccia
Arianna Donella-Deana
Edoardo Marchesi
Federica Andreoni
Franca Formelli
Frank Boschelli
Leonardo Scapozza
Miriam Puttini
Rocco Piazza
Sara Redaelli
P304
11314-11322
P356
10.1158/0008-5472.CAN-06-1199
P407
P577
2006-11-17T00:00:00Z